SlateStone Wealth LLC Increases Holdings in Kenvue Inc. (NYSE:KVUE)

SlateStone Wealth LLC increased its position in Kenvue Inc. (NYSE:KVUE) by 3.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 28,685 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. SlateStone Wealth LLC’s holdings in Kenvue were worth $612,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Nicholas Company Inc. increased its holdings in Kenvue by 7.9% in the 4th quarter. Nicholas Company Inc. now owns 2,623,887 shares of the company’s stock worth $56,020,000 after acquiring an additional 191,103 shares during the last quarter. Corient Private Wealth LLC increased its holdings in Kenvue by 601.8% in the 4th quarter. Corient Private Wealth LLC now owns 339,848 shares of the company’s stock worth $7,256,000 after acquiring an additional 291,425 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in Kenvue by 159.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 488,258 shares of the company’s stock worth $10,424,000 after acquiring an additional 300,137 shares during the last quarter. Natixis Advisors LLC increased its holdings in Kenvue by 3.9% in the 4th quarter. Natixis Advisors LLC now owns 1,842,646 shares of the company’s stock worth $39,341,000 after acquiring an additional 69,683 shares during the last quarter. Finally, Brandes Investment Partners LP increased its holdings in Kenvue by 3.2% in the 4th quarter. Brandes Investment Partners LP now owns 2,940,712 shares of the company’s stock worth $62,784,000 after acquiring an additional 90,387 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Barclays decreased their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Finally, UBS Group cut their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $23.75.

Kenvue Stock Performance

Shares of KVUE opened at $22.81 on Monday. The company has a market cap of $43.59 billion, a PE ratio of 43.03, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $21.84 and a 200-day moving average price of $22.39. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.60%. Kenvue’s dividend payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.